Pancreatic Cancer Research

ResearcherGarvan Institute of Medical ResearchActive in the last 2 years

Thomas R. Jeffry Evans

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5201-885X; OpenAlex author ID A5014220064. Sources: OpenAlex.

Their work

Papers
13
Trials
0
Grants
0
Labs led
0
Collaborators
51
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 13

  1. Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis. Co-author DOI 10.1126/sciadv.adq4416↗
  2. Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response. Co-author DOI 10.1126/sciadv.adl1197↗
  3. Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients. Co-author PMID 36628279↗
  4. Targeting Multiple Effector Pathways in Pancreatic Ductal Adenocarcinoma with a G-Quadruplex-Binding Small Molecule. Co-author DOI 10.1021/acs.jmedchem.7b01781↗
  5. Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdw607↗
  6. Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Co-author DOI 10.1126/scitranslmed.aai8504↗
  7. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ccell.2016.04.014↗
  8. mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-16-0810↗
  9. Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug effic… Co-author DOI 10.15252/emmm.201404827↗
  10. A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. Co-author DOI 10.1007/s00280-014-2470-4↗
  11. Targeting mTOR dependency in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2013-306202↗
  12. Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of src in pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-12-4545↗
  13. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarc… Co-author DOI 10.1158/1078-0432.ccr-11-0679↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jennifer P. Morton · 8 shared papers, 2012–2022 · strength 0.40
  2. Owen James Sansom · 7 shared papers, 2012–2022 · strength 0.34
  3. Nigel Balfour Jamieson · 5 shared papers, 2012–2022 · strength 0.27
  4. David Kuang-Fu Chang · 4 shared papers, 2014–2022 · strength 0.24
  5. Andrew Victor Biankin · 4 shared papers, 2014–2022 · strength 0.24
  6. Karin A. Oien · 4 shared papers, 2012–2022 · strength 0.22
  7. Colin J. McKay · 4 shared papers, 2012–2022 · strength 0.22
  8. Asif Ali · 2 shared papers, 2012–2022 · strength 0.16
  9. C. Ross Carter · 4 shared papers, 2012–2016 · strength 0.14
  10. Jaswinder Singh Samra · 1 shared paper, 2022 · strength 0.13
  11. Niccola Funel · 1 shared paper, 2022 · strength 0.13
  12. Anthony James Gill · 1 shared paper, 2022 · strength 0.13
  13. Elisa Giovannetti · 1 shared paper, 2022 · strength 0.13
  14. Adam Enver Frampton · 1 shared paper, 2022 · strength 0.13
  15. Kurt I. Anderson · 3 shared papers, 2013–2015 · strength 0.10
  16. Simon T. Barry · 2 shared papers, 2016 · strength 0.09
  17. Colin William Steele · 2 shared papers, 2015–2016 · strength 0.08
  18. Peter J. Bailey · 2 shared papers, 2015–2016 · strength 0.08
  19. Paul Timpson · 2 shared papers, 2013–2015 · strength 0.06
  20. Douglas C. Morran · 2 shared papers, 2012–2014 · strength 0.06
  21. Mekala Gunaratnam · 1 shared paper, 2018 · strength 0.06
  22. Stephan A. Ohnmacht · 1 shared paper, 2018 · strength 0.06
  23. Ahmed A. Ahmed · 1 shared paper, 2018 · strength 0.06
  24. Chiara Marchetti · 1 shared paper, 2018 · strength 0.06
  25. Stephen Neidle · 1 shared paper, 2018 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.